Cetuximab (Erbitux®) is a recombinant, chimeric monoclonal antibody that binds with high
affinity to the extracellular ligand-binding domain of human epidermal growth factor receptor …

Background: Cutaneous squamous cell carcinomas (CSCC) are very common. Localized
CSCC are cured by surgery and/or radiotherapy and have a better prognosis than locally …

PURPOSE: To evaluate the efficacy and safety of first-line single-agent cetuximab in fit
elderly patients with metastatic colorectal cancer, as well as potential molecular predictive …

Cetuximab is a chimeric mouse–human monoclonal antibody that targets the human
epidermal growth factor receptor (EGFR). However, EGFR expression determined by …

Colorectal cancer is the second most common cancer, representing 13% of all diagnosed
cancers. Cetuximab is a recombinant chimeric monoclonal IgG1 antibody and epidermal …

Background: Nasopharyngeal carcinoma (NPC) is the most common head and neck cancer
in southern China and South East Asia. Epidermal growth factor receptor (EGFR) has been …

Purpose To evaluate the efficacy and safety of the epidermal growth factor receptor–directed
monoclonal antibody cetuximab administered as a single agent in patients with recurrent …

Purpose To evaluate the antitumor activity and toxicity of single-agent cetuximab in patients
with chemotherapy-refractory colorectal cancer whose tumors express the epidermal growth …

Objective: In patients with head and neck squamous cell carcinoma (HNSCC), cetuximab [a
monoclonal antibody targeting epidermal growth factor receptor (EGFR)] has been shown to …

The primary purpose of this paper is to present the available evidence for the administration
of cetuximab on an every-2-weeks basis in combination with irinotecan in metastatic …